SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that data from its investigational bacteriophage programs,...
Read more about AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
Valencia, CA, Perth, Australia and London, United Kingdom, 7 April 2017 – link here
Read more about FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell®
Entries this year came from as far afield as Kaitaia and Invercargill which have resulted in a record number of entries being received, up 30% on last year.
Read more about Adherium chosen as Finalist in NZ Hi-Tech Awards